Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  Google Scholar 

Aleskandarany MA, Vandenberghe ME, Marchiò C, Ellis IO, Sapino A, Rakha EA (2018) Tumour heterogeneity of breast cancer: from morphology to personalised medicine. PAT 85(1–2):23–34. https://doi.org/10.1159/000477851

Article  Google Scholar 

Guo L, Kong D, Liu J et al (2023) Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol 12(1):3. https://doi.org/10.1186/s40164-022-00363-1

Article  PubMed  PubMed Central  Google Scholar 

Masuda S, Nakanishi Y (2023) Application of immunohistochemistry in clinical practices as a standardized assay for breast cancer. Acta Histochem Cytochem 56(1):1–8. https://doi.org/10.1267/ahc.22-00050

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Lei J, Wang J, Lian CL, Hua L, Yang LC, Wu SG (2020) Validation of the 8th edition of the American joint committee on cancer pathological prognostic staging for young breast cancer patients. Aging (Albany NY) 12(8):7549–7560. https://doi.org/10.18632/aging.103111

Article  CAS  PubMed  Google Scholar 

Cserni G, Chmielik E, Cserni B, Tot T (2018) The new TNM-based staging of breast cancer. Virchows Arch 472(5):697–703. https://doi.org/10.1007/s00428-018-2301-9

Article  PubMed  Google Scholar 

Rakha EA, Reis-Filho JS, Baehner F et al (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12(4):207. https://doi.org/10.1186/bcr2607

Article  PubMed  PubMed Central  Google Scholar 

Fong Y, Evans J, Brook D, Kenkre J, Jarvis P, Gower-Thomas K (2015) The Nottingham prognostic index: five- and ten-year data for all-cause survival within a screened population. Ann R Coll Surg Engl 97(2):137–139. https://doi.org/10.1308/003588414X14055925060514

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tschodu D, Ulm B, Bendrat K et al (2022) Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: combining the Nottingham prognostic index with gene expressions into a hybrid signature. PLoS ONE 17(2):e0261035. https://doi.org/10.1371/journal.pone.0261035

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. https://doi.org/10.1038/415530a

Article  PubMed  Google Scholar 

Munkácsy G, Santarpia L, Győrffy B (2022) Gene expression profiling in early breast cancer-patient stratification based on molecular and tumor microenvironment features. Biomedicines 10(2):248. https://doi.org/10.3390/biomedicines10020248

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cobleigh MA, Tabesh B, Bitterman P et al (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11(24 Pt 1):8623–8631. https://doi.org/10.1158/1078-0432.CCR-05-0735

Article  CAS  PubMed  Google Scholar 

Cardoso F, Van’t Veer LJ, Bogaerts J et al (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729. https://doi.org/10.1056/NEJMoa1602253

Article  CAS  PubMed  Google Scholar 

Filipits M, Rudas M, Jakesz R et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18):6012–6020. https://doi.org/10.1158/1078-0432.CCR-11-0926

Article  CAS  PubMed  Google Scholar 

Neuber AC, Tostes CH, Ribeiro AG et al (2022) The biobank of barretos cancer hospital: 14 years of experience in cancer research. Cell Tissue Bank 23(2):271–284. https://doi.org/10.1007/s10561-021-09941-9

Article  PubMed  Google Scholar 

Cree IA, Tan PH, Travis WD et al (2021) Counting mitoses: si(ze) matters! Mod Pathol 34(9):1651–1657. https://doi.org/10.1038/s41379-021-00825-7

Article  PubMed  PubMed Central  Google Scholar 

Tan PH, Ellis I, Allison K et al (2020) The 2019 world health organization classification of tumours of the breast. Histopathology 77(2):181–185. https://doi.org/10.1111/his.14091

Article  PubMed  Google Scholar 

nCounter Breast Cancer 360. NanoString. Accessed Dec 28, 2022. https://nanostring.com/products/ncounter-assays-panels/oncology/breast-cancer-360/

Lashen A, Toss MS, Fadhil W, Oni G, Madhusudan S, Rakha E (2023) Evaluation oncotype DX® 21-gene recurrence score and clinicopathological parameters: a single institutional experience. Histopathology 82(5):755–766. https://doi.org/10.1111/his.14863

Article  PubMed  Google Scholar 

Miller DV, Leontovich AA, Lingle WL et al (2004) Utilizing Nottingham prognostic index in microarray gene expression profiling of breast carcinomas. Mod Pathol 17(7):756–764. https://doi.org/10.1038/modpathol.3800114

Article  CAS  PubMed  Google Scholar 

Fäldt Beding A, Larsson P, Helou K, Einbeigi Z, Parris TZ (2022) Pan-cancer analysis identifies BIRC5 as a prognostic biomarker. BMC Cancer 22(1):322. https://doi.org/10.1186/s12885-022-09371-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayley R, Ward C, Garcia P (2020) MYBL2 amplification in breast cancer: molecular mechanisms and therapeutic potential. Biochim Biophys Acta Rev Cancer 1874(2):188407. https://doi.org/10.1016/j.bbcan.2020.188407

Article  CAS  PubMed  Google Scholar 

Lu ZN, Song J, Sun TH, Sun G (2021) UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway. Chin Med J (Engl) 134(20):2465–2474. https://doi.org/10.1097/CM9.0000000000001708

Article  CAS  PubMed  Google Scholar 

Liao GB, Li XZ, Zeng S et al (2018) Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal 16(1):57. https://doi.org/10.1186/s12964-018-0266-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Xu B, Yuan P et al (2012) TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat 135(2):531–537. https://doi.org/10.1007/s10549-012-2167-5

Article  CAS  PubMed  Google Scholar 

Lim N, Townsend PA (2020) Cdc6 as a novel target in cancer: oncogenic potential, senescence and subcellular localisation. Int J Cancer 147(6):1528–1534. https://doi.org/10.1002/ijc.32900

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minchin RF, Butcher NJ (2018) Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance. BMC Genomics 19(1):513. https://doi.org/10.1186/s12864-018-4894-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edechi CA, Ikeogu NM, Akaluka GN et al (2021) The prolactin inducible protein modulates antitumor immune responses and metastasis in a mouse model of triple negative breast cancer. Front Oncol 11:639859. https://doi.org/10.3389/fonc.2021.639859

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang D, Li L, Xu Z, Chen X (2023) Targeting FOS attenuates malignant phenotypes of breast cancer: evidence from in silico and in vitro studies. J Biochem Mol Toxicol 37(7):e23358. https://doi.org/10.1002/jbt.23358